Gentherapien für neuromuskuläre Erkrankungen
BackgroundFor a long time the treatment of neuromuscular diseases was considered to be purely symptomatic. Due to new technologies in recent years novel causal forms of treatment could be developed. Gene therapies for spinal muscular atrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrop...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Deutsch |
| Veröffentlicht: |
8. Juli 2019
|
| In: |
Der Nervenarzt
Year: 2019, Jahrgang: 90, Heft: 8, Pages: 809-816 |
| ISSN: | 1433-0407 |
| DOI: | 10.1007/s00115-019-0761-z |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1007/s00115-019-0761-z Verlag: https://doi.org/10.1007/s00115-019-0761-z 
|
| Verfasserangaben: | Afshin Saffari, Markus Weiler, Georg Friedrich Hoffmann, Andreas Ziegler |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1679173502 | ||
| 003 | DE-627 | ||
| 005 | 20230426155216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00115-019-0761-z |2 doi | |
| 035 | |a (DE-627)1679173502 | ||
| 035 | |a (DE-599)KXP1679173502 | ||
| 035 | |a (OCoLC)1341248222 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a ger | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Saffari, Afshin |d 1988- |e VerfasserIn |0 (DE-588)1076753302 |0 (DE-627)835291251 |0 (DE-576)445631406 |4 aut | |
| 245 | 1 | 0 | |a Gentherapien für neuromuskuläre Erkrankungen |c Afshin Saffari, Markus Weiler, Georg Friedrich Hoffmann, Andreas Ziegler |
| 264 | 1 | |c 8. Juli 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.10.2019 | ||
| 520 | |a BackgroundFor a long time the treatment of neuromuscular diseases was considered to be purely symptomatic. Due to new technologies in recent years novel causal forms of treatment could be developed. Gene therapies for spinal muscular atrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, myotubular myopathy and hereditary motor and sensory neuropathy type 1A are currently being evaluated in clinical trials. Initial preliminary results are promising and the first preparation onasemnogene abeparvovec-xioi (Zolgensma®) for the treatment of spinal muscular atrophy has recently been approved by the U.S. Food and Drug Administration (FDA).ObjectiveThis review describes the principles of gene therapy, summarizes the interim results published so far and provides an overview of currently active or soon to be initiated gene therapy trials.ConclusionGene therapies have the potential to significantly influence the course of neuromuscular diseases. First positive intermediate results have been published and the first treatment has recently been approved in the USA. Long-term data on sustained effects and toxicity of gene therapies are not yet available. These novel treatment options will present new challenges for the healthcare systems concerning diagnosis, treatment and reimbursement. | ||
| 650 | 4 | |a Duchenne muscular dystrophy | |
| 650 | 4 | |a Duchenne-Muskeldystrophie | |
| 650 | 4 | |a Gene therapy | |
| 650 | 4 | |a Gentherapie | |
| 650 | 4 | |a Neuromuscular diseases | |
| 650 | 4 | |a Neuromuskuläre Erkrankungen | |
| 650 | 4 | |a Spinal muscular atrophy | |
| 650 | 4 | |a Spinale Muskelatrophie | |
| 700 | 1 | |a Weiler, Markus |d 1972- |e VerfasserIn |0 (DE-588)123920256 |0 (DE-627)706474236 |0 (DE-576)293943079 |4 aut | |
| 700 | 1 | |a Hoffmann, Georg F. |d 1957- |e VerfasserIn |0 (DE-588)115652868 |0 (DE-627)077386116 |0 (DE-576)261230042 |4 aut | |
| 700 | 1 | |a Ziegler, Andreas |d 1979- |e VerfasserIn |0 (DE-588)134123530 |0 (DE-627)560894201 |0 (DE-576)278444253 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Nervenarzt |d Berlin : Springer, 1996 |g 90(2019), 8, Seite 809-816 |h Online-Ressource |w (DE-627)25463835X |w (DE-600)1462945-8 |w (DE-576)074531468 |x 1433-0407 |7 nnas |a Gentherapien für neuromuskuläre Erkrankungen |
| 773 | 1 | 8 | |g volume:90 |g year:2019 |g number:8 |g pages:809-816 |g extent:8 |a Gentherapien für neuromuskuläre Erkrankungen |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00115-019-0761-z |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00115-019-0761-z |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191021 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 134123530 |a Ziegler, Andreas |m 134123530:Ziegler, Andreas |d 910000 |d 910500 |e 910000PZ134123530 |e 910500PZ134123530 |k 0/910000/ |k 1/910000/910500/ |p 4 |y j | ||
| 998 | |g 123920256 |a Weiler, Markus |m 123920256:Weiler, Markus |d 910000 |d 911100 |e 910000PW123920256 |e 911100PW123920256 |k 0/910000/ |k 1/910000/911100/ |p 2 | ||
| 998 | |g 115652868 |a Hoffmann, Georg F. |m 115652868:Hoffmann, Georg F. |d 910000 |d 910500 |e 910000PH115652868 |e 910500PH115652868 |k 0/910000/ |k 1/910000/910500/ |p 3 | ||
| 998 | |g 1076753302 |a Saffari, Afshin |m 1076753302:Saffari, Afshin |d 910000 |d 910500 |e 910000PS1076753302 |e 910500PS1076753302 |k 0/910000/ |k 1/910000/910500/ |p 1 |x j | ||
| 999 | |a KXP-PPN1679173502 |e 3525698712 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Afshin Saffari, Markus Weiler, Georg Friedrich Hoffmann, Andreas Ziegler"]},"id":{"eki":["1679173502"],"doi":["10.1007/s00115-019-0761-z"]},"physDesc":[{"extent":"8 S."}],"recId":"1679173502","origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"8. Juli 2019"}],"relHost":[{"titleAlt":[{"title":"Organ von: Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde ; Mitteilungsblatt von: Deutsche Gesellschaft für Neurologie, Gesellschaft Österreichischer Nervenärzte und Psychiater ; begründet 1928"}],"pubHistory":["Nachgewiesen 67.1996,8 -"],"part":{"volume":"90","year":"2019","extent":"8","text":"90(2019), 8, Seite 809-816","issue":"8","pages":"809-816"},"id":{"zdb":["1462945-8"],"issn":["1433-0407"],"eki":["25463835X"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"25463835X","disp":"Gentherapien für neuromuskuläre ErkrankungenDer Nervenarzt","origin":[{"publisher":"Springer ; Springer","dateIssuedKey":"1996","dateIssuedDisp":"1996-","publisherPlace":"Berlin ; Heidelberg ; Berlin ; Heidelberg ; New York, NY"}],"note":["Gesehen am 18.10.06","Ungezählte Beil.: Supplement"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["ger"],"title":[{"title_sort":"Nervenarzt","title":"Der Nervenarzt","subtitle":"Organ der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde ; Mitteilungsblatt der Deutschen Gesellschaft für Neurologie"}]}],"person":[{"display":"Saffari, Afshin","role":"aut","given":"Afshin","family":"Saffari"},{"display":"Weiler, Markus","role":"aut","given":"Markus","family":"Weiler"},{"role":"aut","given":"Georg F.","family":"Hoffmann","display":"Hoffmann, Georg F."},{"given":"Andreas","role":"aut","family":"Ziegler","display":"Ziegler, Andreas"}],"language":["ger"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 21.10.2019"],"title":[{"title":"Gentherapien für neuromuskuläre Erkrankungen","title_sort":"Gentherapien für neuromuskuläre Erkrankungen"}]} | ||
| SRT | |a SAFFARIAFSGENTHERAPI8201 | ||